NT-proBNP and predictors of event free survival and left ventricular systolic function recovery in peripartum cardiomyopathy
- PMID: 35358637
- PMCID: PMC10007968
- DOI: 10.1016/j.ijcard.2022.03.052
NT-proBNP and predictors of event free survival and left ventricular systolic function recovery in peripartum cardiomyopathy
Abstract
Objective: To determine predictors of adverse outcomes in peripartum cardiomyopathy (PPCM).
Methods and results: We conducted a multi-center cohort study across four centers to identify subjects with PPCM with the following criteria: LVEF <40%, development of heart failure within the last month of pregnancy or within 5 months of delivery and no other identifiable cause of heart failure with reduced ejection fraction. Outcomes included 1) survival free from major adverse events (need for extra-corporeal membrane oxygenation, ventricular assist device, orthotopic heart transplantation or death) and 2) LVEF recovery ≥ 50%. Using a univariate logistic regression analysis, we identified significant clinical predictors of these outcomes, which were then used to create multivariable models. NT-proBNP at the time of diagnosis was examined both as a continuous variable (log transformed) in logistic regression and as a dichotomous variable (values above and below the median) using the log-rank test. In all, 237 women (1993 to 2017) with 736.4 person-years of follow-up, met criteria for PPCM. Participants had a mean age of 32.4 ± 6.7 years, mean BMI 30.6 ± 7.8 kg/m2; 63% were White. After median follow-up of 3.6 years (IQR 1.1-7.8), 113 (67%) had LVEF recovery, and 222 (94%) had survival free from adverse events. Significant predictors included gestational age, gravidity, systolic blood pressure, smoking, heart rate, initial LVEF, and diuretic use. In a subset of 110 patients with measured NTproBNP levels, we found a higher event free survival for women with NTproBNP <2585 pg/ml (median) as compared to women with NTproBNP ≥2585 pg/ml (log-rank test p-value 0.018).
Conclusion: Gestational age, gravidity, current or past tobacco use, systolic blood pressure, heart rate, initial LVEF and diuretic requirement at the time of diagnosis were associated with survival free from adverse events and LVEF recovery. Initial NT-proBNP was significantly associated with event free survival.
Keywords: Adverse outcomes; NT-proBNP; Peripartum cardiomyopathy; Pregnancy associated heart failure.
Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest
The authors have no conflict of interest.
Figures
Similar articles
-
Clinical predictors of right ventricular dysfunction and association with adverse outcomes in peripartum cardiomyopathy.ESC Heart Fail. 2024 Feb;11(1):422-432. doi: 10.1002/ehf2.14583. Epub 2023 Nov 29. ESC Heart Fail. 2024. PMID: 38030384 Free PMC article.
-
Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM).Clin Res Cardiol. 2021 Aug;110(8):1259-1269. doi: 10.1007/s00392-021-01808-z. Epub 2021 Feb 8. Clin Res Cardiol. 2021. PMID: 33555408 Free PMC article.
-
Electrocardiographic findings in peripartum cardiomyopathy.Clin Cardiol. 2019 May;42(5):524-529. doi: 10.1002/clc.23171. Epub 2019 Mar 29. Clin Cardiol. 2019. PMID: 30843220 Free PMC article.
-
Prognostic value of various markers in recovery from peripartum cardiomyopathy: a systematic review and meta-analysis.ESC Heart Fail. 2022 Oct;9(5):3483-3495. doi: 10.1002/ehf2.14085. Epub 2022 Jul 26. ESC Heart Fail. 2022. PMID: 35883253 Free PMC article.
-
Meta-Analysis of Long-Term (>1 Year) Cardiac Outcomes of Peripartum Cardiomyopathy.Am J Cardiol. 2023 May 1;194:71-77. doi: 10.1016/j.amjcard.2023.01.043. Epub 2023 Mar 28. Am J Cardiol. 2023. PMID: 36989549 Review.
Cited by
-
The Utilization and Interpretation of Cardiac Biomarkers During Pregnancy: JACC: Advances Expert Panel.JACC Adv. 2022 Aug 26;1(3):100064. doi: 10.1016/j.jacadv.2022.100064. eCollection 2022 Aug. JACC Adv. 2022. PMID: 38938393 Free PMC article. Review.
-
Clinical predictors of right ventricular dysfunction and association with adverse outcomes in peripartum cardiomyopathy.ESC Heart Fail. 2024 Feb;11(1):422-432. doi: 10.1002/ehf2.14583. Epub 2023 Nov 29. ESC Heart Fail. 2024. PMID: 38030384 Free PMC article.
-
Diagnosis and management of peripartum cardiomyopathy and recurrence risk.Int J Cardiol Congenit Heart Dis. 2024 Jul 19;17:100530. doi: 10.1016/j.ijcchd.2024.100530. eCollection 2024 Sep. Int J Cardiol Congenit Heart Dis. 2024. PMID: 39711771 Free PMC article.
-
The association of heart rate with adverse outcomes and recurrent heart failure hospitalization in peripartum cardiomyopathy.Clin Res Cardiol. 2025 Feb 24. doi: 10.1007/s00392-025-02615-6. Online ahead of print. Clin Res Cardiol. 2025. PMID: 39992386
-
Biomarkers in Peripartum Cardiomyopathy-What We Know and What Is Still to Be Found.Biomolecules. 2024 Jan 12;14(1):103. doi: 10.3390/biom14010103. Biomolecules. 2024. PMID: 38254703 Free PMC article. Review.
References
-
- Elkayam U, Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management, J. Am. Coll. Cardiol 58 (2011) 659–670. - PubMed
-
- Gunderson EP, Croen LA, Chiang V, et al., Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes, Obstet. Gynecol 118 (2011) 583–591. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous